San Diego, USA — May 24, 2024. Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announces the completion of a global collaboration agreement with the Shanghai Model Organisms Center (SMOC). This five-year agreement extends the existing partnership and will provide unique immuno-oncology platforms and services from all Crown Bioscience facilities worldwide.
- The purchase and supply of a broad range of genetically engineered mouse models, including thousands of knock-in and knock-out humanized models,
- Custom development of GEMM models and MuPrimeTM (Crown Bioscience’s tumor homograft models) leveraging SMOC-engineered mice.
Globally, Crown Bioscience research affiliates will benefit from uniform pricing, comprehensive IP protection, and licensing rights. This uniformity is accompanied by a shared commitment to research excellence, unrivaled quality standards, and scientific innovation.
- Unprecedented Access: Immediate access to SMOC’s extensive library, featuring over 6,000 off-the-shelf mouse models and more than 11,000 established genetically engineered mouse prototypes.
- Consistent Supply Chain: A reliable source of genetically engineered cell lines and murine models, alongside highly translational humanized models.
- Global Strategic Synergy: Fostering a global strategic partnership, extending beyond procurement, that enhances both entities' capabilities and offerings.
Through this collaboration, Crown Bioscience and SMOC will help bridge the gap between scientific discovery and clinical application and foster the continuous growth and evolution of global research initiatives.
Click here for more information on our innovative immuno-oncology platforms and services.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...